KN
Kane Biotech Inc.
KNE.V · TSXV
$0.03 -16.67% (-$0.01)
1M -16.67%
Market Cap $6.15M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 158.88x
EV/EBITDA N/A
P/B N/A
Growth
100 /100
Growing Rev. growth 39.76%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak Net margin 6,980.20%
Op. margin 8,113.83%
FCF margin 6,255.55%
Quality
0 /100
Poor ROA 121.29%
Asset turnover 0.02x
ROIC 312.58%
Debt
6 /100
High Int. coverage -17.23x
Current ratio 0.61x
Net debt/EBITDA N/A
Stability
26 /100
Unstable Rev. volatility 773.94%
EPS volatility 34.18%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o KNE.V
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Huizinga
Employees
32
Headquarters
Winnipeg
Prihajajoči dogodki
26 NOV.
Earnings
Upcoming earnings report